First patient included!

The first patient has been included on April 10th in the Mount Sinai Hospital, New York (USA), April 24th in The National Cancer Institute of Milan (Italy) and on April 28th in the University Hospitals of Leicester (UK).

The set-up of the REQUITE observational study is nearly complete and is running on schedule.

By the end of March 2014, full ethics approval had been granted in Italy, Germany, Spain, USA and the UK.

The REQUITE observational study is being managed by colleagues at the German Cancer Research Centre (DKFZ) in Heidelberg, and is supported by colleagues at CIGMR, University of Manchester who are responsible for all the samples that will be collected.